Dolutegravir
| CAS No. | 1051375-16-6 | Cat. No. | BCP02329 |
| Name | Dolutegravir | ||
| Synonyms | GSK1349572;GSK 1349572;GSK-1349572;S/GSK1349572;S-349572; | ||
| Formula | C20H19F2N3O5 | M. Wt | 419.38 |
| Description | Dolutegravir is an orally bioavailable integrase strand-transfer inhibitor (INSTI), with activity against human immunodeficiency virus type 1 (HIV-1) infection. Upon oral administration, dolutegravir binds to the active site of integrase, an HIV enzyme that catalyzes the transfer of viral genetic material into human chromosomes. This prevents integrase from binding to retroviral deoxyribonucleic acid (DNA), and blocks the strand transfer step, which is essential for the HIV replication cycle. This prevents HIV-1 replication. | ||
| Pathways | Protease/Metabolic Enzyme Microbiology/Virology | ||
| Targets | Integrase HIV | ||
|
Simultaneous quantification of tenofovir, emtricitabine, rilpivirine, elvitegravir and dolutegravir in mouse biological matrices by LC-MS/MS and its application to a pharmacokinetic study
Publications Citing of Biochempartner's Dolutegravir(CAS:1051375-16-6) |
|
Development and validation of LC–MS/MS method for quantification of bictegravir in human plasma and its application to an intracellular uptake study
Publications Citing of Biochempartner's Dolutegravir(CAS:1051375-16-6) |
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.